31.83
-2.54 (-7.39%)
| Penutupan Terdahulu | 34.37 |
| Buka | 33.83 |
| Jumlah Dagangan | 519,311 |
| Purata Dagangan (3B) | 601,083 |
| Modal Pasaran | 1,555,837,696 |
| Harga / Jualan (P/S) | 3.35 |
| Harga / Buku (P/B) | 3.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2025 - 5 May 2025 |
| Margin Keuntungan | -9.61% |
| Margin Operasi (TTM) | -11.69% |
| EPS Cair (TTM) | -0.950 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.60% |
| Nisbah Semasa (MRQ) | 3.65 |
| Aliran Tunai Operasi (OCF TTM) | 12.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.42 M |
| Pulangan Atas Aset (ROA TTM) | -4.09% |
| Pulangan Atas Ekuiti (ROE TTM) | -9.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Bercampur | |
| Stok | AtriCure, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.49% |
| % Dimiliki oleh Institusi | 98.00% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (Citizens Capital Markets, 88.50%) | Beli |
| 60.00 (JMP Securities, 88.50%) | Beli | |
| Median | 50.50 (58.66%) | |
| Rendah | 45.00 (Oppenheimer, 41.38%) | Beli |
| Purata | 51.50 (61.80%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 36.35 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens Capital Markets | 02 Apr 2025 | 60.00 (88.50%) | Beli | 31.83 |
| Canaccord Genuity | 28 Mar 2025 | 52.00 (63.37%) | Beli | 31.83 |
| 13 Feb 2025 | 66.00 (107.35%) | Beli | 39.59 | |
| JP Morgan | 27 Mar 2025 | 46.00 (44.52%) | Beli | 34.37 |
| 11 Feb 2025 | 51.00 (60.23%) | Beli | 41.51 | |
| Needham | 27 Mar 2025 | 51.00 (60.23%) | Beli | 34.37 |
| 21 Mar 2025 | 51.00 (60.23%) | Beli | 33.54 | |
| JMP Securities | 13 Feb 2025 | 60.00 (88.50%) | Beli | 39.59 |
| 10 Feb 2025 | 60.00 (88.50%) | Beli | 42.02 | |
| Oppenheimer | 13 Feb 2025 | 45.00 (41.38%) | Beli | 39.59 |
| Piper Sandler | 13 Feb 2025 | 50.00 (57.08%) | Beli | 39.59 |
| Stifel | 13 Feb 2025 | 48.00 (50.80%) | Beli | 39.59 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Mar 2025 | Pengumuman | AtriCure to Host Analyst & Investor Day on March 26, 2025 |
| 12 Feb 2025 | Pengumuman | AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results |
| 22 Jan 2025 | Pengumuman | AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results |
| 13 Jan 2025 | Pengumuman | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |